Drug discovery and development – Page 27
-
BusinessAstraZeneca shares tumble after antibody failure
Imfinzi and tremelimumab checkpoint inhibitor pairing fails to beat chemotherapy in lung cancer
-
BusinessNovartis coasts towards first CAR-T approval
Unanimous recommendation for CTL019 ahead of October decision builds confidence in T-cell genetic reprogramming
-
Opinion(+)-Pleuromutilin
Total synthesis is sometimes the only way to explore the chemical space around a natural product
-
ResearchSimplified structure eases antibiotic synthesis
New analogues of the potent antibiotic teixobactin could be instrumental in the fight against multi-drug resistant pathogens
-
OpinionMaking enough of a difference
What if the needle in the drug development haystack ends up being too small to be useful?
-
BusinessFDA approves first sickle cell drug in almost two decades
Glutamine-based drug is the first approved for children over 5
-
BusinessAmplifying intelligent drug design
This year’s Chemistry World Entrepreneur of the year is Andrew Hopkins of start-up Exscientia and the University of Dundee, UK
-
NewsEuropean ‘One Health’ plan aims to curb antimicrobial resistance
Action plan treats human and animal health as interconnected
-
ArticleSygnature Discovery
Sygnature Discovery is part of an innovative partnership to bolster the life science sector in Nottingham
-
OpinionUnpicking a clinical trial death
A new study shows up off-target effects of a drug that proved deadly, and highlights the pitfalls of drug discovery
-
FeatureAccess to drugs: a failure of pharma?
Many people around the world are either unable to afford the drugs they need, or their conditions have not been addressed by pharma R&D. Sarah Houlton investigates
-
ResearchModified antibiotic beats superbug resistance
Adding functional groups to vancomycin gives it extra modes of attack against resistant bacteria
-
OpinionDrug pricing must be more transparent
Pricing is a complex issue - how can we make it clearer?
-
BusinessPollution from Indian drugmakers drives drug resistance
Areas around manufacturing sites still heavily contaminated with antimicrobials and breeding multidrug-resistant pathogens
-
ResearchHow total synthesis is creating antibiotics
Macrolide synthesis could reinvigorate the antibiotic pipeline
-
FeatureCovalent inhibitor drugs
Exceptions to a long-held rule against chemically bonding to biological targets are powering new cancer medicines, finds Andy Extance
-
ResearchMaple syrup enhances antibiotics
A phenol-rich mixture extracted from maple syrup allows much smaller doses of antibacterial drugs to achieve the same results
-
NewsHow we are fighting tropical diseases
Repellents and vaccines are useful but still need further improvement
-
BusinessExpanding precision medicine beyond cancer
Exclusive interview with Koustubh Ranade, vice president of R&D at MedImmune
-
